SCHEMBL8434248

SCHEMBL8434248

Cc1ccnc(S(=O)(=O)O)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
UHRF1 Q96T88 1/20 0.46
CCR1 P32246 1/20 0.46
CCR5 P51681 1/20 0.46
CCR8 P51685 1/20 0.46
KDM4E B2RXH2 8/20 0.43
KMT2A Q03164 2/20 0.43
MEN1 O00255 1/20 0.43
NOS3 P29474 1/20 0.43
NOS1 P29475 1/20 0.43
NOS2 P35228 1/20 0.43
PLAU P00749 1/20 0.40
ALDH1A1 P00352 8/20 0.39
HPGD P15428 2/20 0.39
FDPS P14324 1/20 0.39
GAA P10253 1/20 0.39
HSD17B10 Q99714 1/20 0.39
CYP2A6 P11509 1/20 0.38
LMNA P02545 2/20 0.38
MAPT P10636 1/20 0.38
HTT P42858 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Fluoride SCHEMBL27839384 0.98 UHRF1 (0.45) UHRF1CCR1CCR5CCR8KDM4E
SCHEMBL2643186 0.81 UHRF1 (0.48) UHRF1CCR1CCR5CCR8KDM4E
SCHEMBL1464557 0.79 UHRF1 (0.46) UHRF1CCR1CCR5CCR8KDM4E
SCHEMBL1824530 0.79 UHRF1 (0.46) UHRF1CCR1CCR5CCR8KDM4E
SCHEMBL3675739 0.79 KDM4E (0.48) UHRF1CCR1CCR5CCR8KDM4E
SCHEMBL30845679 0.79 KDM4E (0.48) UHRF1CCR1CCR5CCR8KDM4E
SCHEMBL2642943 0.78 UHRF1 (0.45) UHRF1CCR1CCR5CCR8KDM4E
SCHEMBL3439204 0.78 UHRF1 (0.45) UHRF1CCR1CCR5CCR8KDM4E
SCHEMBL31527805 0.78 KDM4E (0.47) UHRF1CCR1CCR5CCR8KDM4E
SCHEMBL8847160 0.77 ALDH1A1 (0.41) CCR1CCR5CCR8KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2501236-B1 N-[2-fluoro-3-(4-amino-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-phenyl]-4-benzenesulfonamide derivatives as Raf protein kinase modulators for the treatment of cancer PLEXXIKON INC (US) 2017-03-29 EP claimed
CN-106458903-B Method for producing heteroaromatic sulfonamide compound 宇部兴产株式会社 2021-02-05 CN disclosed
CN-108950645-B Aluminum and aluminum alloy anodic oxidation nickel-free sealing agent 上海铝通化学科技有限公司 2020-10-23 CN disclosed
US-20200035419-A1 PHOTOELECTRIC CONVERSION ELEMENT, SOLAR CELL, METHOD FOR MANUFACTURING PHOTOELECTRIC CONVERSION ELEMENT, AND PHOTOSENSITIVE-LAYER-FORMING COMPOSITION FUJIFILM CORPORATION (JP) 2020-01-30 US disclosed
EP-3509117-A1 PHOTOELECTRIC CONVERSION ELEMENT, SOLAR BATTERY, METHOD FOR MANUFACTURING PHOTOELECTRIC CONVERSION ELEMENT, AND SURFACE TREATMENT AGENT FOR PEROVSKITE-TYPE CRYSTAL FILM FUJIFILM Corporation (JP) 2019-07-10 EP disclosed
US-20190189362-A1 PHOTOELECTRIC CONVERSION ELEMENT, SOLAR CELL, METHOD FOR MANUFACTURING PHOTOELECTRIC CONVERSION ELEMENT, AND SURFACE TREATING AGENT FOR PEROVSKITE-TYPE CRYSTAL FILM FUJIFILM CORPORATION (JP) 2019-06-20 US disclosed
EP-3156395-B1 METHOD FOR PRODUCING HETEROAROMATIC SULFONAMIDE COMPOUND UBE INDUSTRIES (JP) 2019-01-09 EP disclosed
CN-108950645-A A kind of aluminium and aluminium alloy anode oxide are without nickel sealer 上海铝通化学科技有限公司 2018-12-07 CN disclosed
US-20170121288-A1 METHOD FOR PRODUCING HETEROAROMATIC SULFONAMIDE COMPOUND UBE INDUSTRIES, LTD. (JP) 2017-05-04 US disclosed
EP-3156395-A1 METHOD FOR PRODUCING HETEROAROMATIC SULFONAMIDE COMPOUND UBE Industries, Ltd. (JP) 2017-04-19 EP disclosed
US-9617267-B2 Compounds and methods for kinase modulation, and indications therefor PLEXXIKON INC. (US) 2017-04-11 US disclosed
EP-2501236-B1 N-[2-fluoro-3-(4-amino-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-phenyl]-4-benzenesulfonamide derivatives as Raf protein kinase modulators for the treatment of cancer PLEXXIKON INC (US) 2017-03-29 EP disclosed
CN-106458903-A Method for producing heteroaromatic sulfonamide compound 宇部兴产株式会社 2017-02-22 CN disclosed
US-20140288070-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC. 2014-09-25 US disclosed
US-8673928-B2 Compounds and methods for kinase modulation, and indications therefor PLEXXIKON INC. (US) 2014-03-18 US disclosed
EP-2501236-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR Plexxikon, Inc. (US) 2012-09-26 EP disclosed
EP-0526849-B1 Substituted N-Fluoropyridiniumsulfonate, intermediates therefor and preparation processes thereof DAIKIN IND LTD (JP) 1999-12-01 EP disclosed
CN-1117294-A Substituted fused pyrazolo compounds and their use as herbicides ZENECA LTD (GB) 1996-02-21 CN disclosed
US-5374732-A Chemical intermediates as fluorination agents DAIKIN INDUSTRIES, LTD. (JP) 1994-12-20 US disclosed
EP-0526849-A1 Novel substituted N-Fluoropyridiniumsulfonate, intermediates therefor and preparation processes thereof DAIKIN INDUSTRIES, LTD. (JP) 1993-02-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170121288-A1 METHOD FOR PRODUCING HETEROAROMATIC SULFONAMIDE COMPOUND PFAS, SULT2A1, ARSA UHRF1 2205/4885CCR1 4496/4885CCR5 4593/4885
US-20140288070-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR BRAF, KRAS, RAF1 UHRF1 2767/4885CCR1 2601/4885CCR5 3581/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.